Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Eur J Pharmacol ; 889: 173619, 2020 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-33011242

RESUMEN

Neuropathic pain is a critical burdensome problem due to the complex interplay of several pathological mechanisms and lack of availability of effective therapeutic interventions. The available therapeutic options are associated with a variety of limitations, including severe side effects, and unmet medical needs, warranting further research to identify and validate potential targets. Adenosine receptors system is a widely studied target, which evidently was successful in alleviation of neuropathic pain in several experimental paradigms, and researchers are putting efforts in building its clinical roadmap. The adenosine receptors act by different mechanisms and targeting adenosine receptors for neuropathic pain includes several important pathways such as p38-mitogen-activated protein kinases (MAPK), extracellular signal-regulated kinases (ERK), brain-derived neurotrophic factor (BDNF) signalling, γ-aminobutyric acid (GABA) as well as the ion channel modulations. Various studies have also shown the relevance of targeting adenosine receptors in chemotherapy-induced neuropathic pain and diabetic neuropathy. Several drugs acting on adenosine receptors have undergone clinical trials for management of neuropathic pain, whereas many other drugs are yet to be studied to find a potential anti-nociceptive agent. In this review, we have discussed the roadmap of adenosine receptors as a potential target for the treatment of neuropathic pain.


Asunto(s)
Agonistas Adrenérgicos/metabolismo , Analgésicos/metabolismo , Neuralgia/metabolismo , Receptores Purinérgicos P1/metabolismo , Transducción de Señal/fisiología , Agonistas Adrenérgicos/administración & dosificación , Analgésicos/administración & dosificación , Animales , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Humanos , Neuralgia/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Ácido gamma-Aminobutírico/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
2.
ACS Chem Neurosci ; 11(9): 1210-1217, 2020 05 06.
Artículo en Inglés | MEDLINE | ID: mdl-32243128

RESUMEN

Alcohol addiction is one of the highly prevalent neurological disorders and a major threat to public health in the 21st century. Alcohol addiction affects people from all age groups and often leads to other serious comorbidities. The pathophysiology of alcohol addiction involves imbalance between the excitatory and inhibitory neurotransmitters in the brain. These changes occur in various regions of the brain including reward circuit such as the ventral tegmental area (VTA), nucleus accumbens (NAc), and prefrontal cortex. In this review, we have discussed several neurochemical circuitries which get manipulated and maladapted during alcohol addiction. To date there is no effective therapeutic intervention in clinics devoid of side effects that can successfully treat the patients suffering from alcohol addiction. Understanding the neurobiological intricacies of alcohol addiction is critical for the development of novel anti-addiction therapeutics. Apart from this, we have also discussed the recent therapeutic milestones for the management of alcohol addiction including vasopressin receptors, corticotrophin-releasing factor, GABA receptors, glucocorticoid receptors, brain stimulation and mindfulness-oriented recovery enhancement.


Asunto(s)
Alcoholismo , Conducta Adictiva , Alcoholismo/tratamiento farmacológico , Humanos , Núcleo Accumbens , Recompensa , Área Tegmental Ventral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...